CABA's rejected, implausibly high analyst target and quality-floor breach reflect the uncertainty typical of a clinical-stage biotech, with elevated short interest and options hedging pricing in a binary outcome.
Thesis pillars
- Rejected Analyst Target Data Issue→Stable
- Quality Floor Breach Cash Burn→Stable
- High Short Interest And Iv→Stable
- +1 more pillar — see the Why tab for full reasoning
Cabaletta Bio, Inc. (CABA) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $3.20: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: High short interest: 18%; Elevated put/call ratio: 1.60; Below-average business quality.
Cabaletta Bio is a late clinical-stage biotechnology company developing engineered T cell therapies, built on its CABA platform, designed to reset the immune system for patients with autoimmune diseases through a one-time cell infusion. Its lead candidate, rese-cel, is in a... Read more
Sell if holding. Engine safety override at $3.20: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: High short interest: 18%; Elevated put/call ratio: 1.60; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.5/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 33d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
About Cabaletta Bio, Inc.
About Cabaletta Bio, Inc.
Cabaletta Bio has no products approved for commercial sale, making its lead product candidate, rese-cel, an off-the-shelf CD19-directed CAR T cell therapy, the clinical anchor of the business. The company initiated a registrational cohort within its RESET-Myositis trial in December 2025 for dermatomyositis and anti-synthetase syndrome, targeting a Biologics License Application submission in 2027, alongside earlier-stage RESET trials evaluating rese-cel in lupus, systemic sclerosis and myasthenia gravis.
Cabaletta's CABA platform is built around the CARTA approach, engineering T cells to deplete all B cells in a single weight-based infusion with the goal of resetting the immune system rather than requiring chronic immunosuppression. Beyond rese-cel, the company's HSV-based enLIGHTEN Discovery Platform has generated linoserpaturev, evaluated in an investigator-sponsored Phase 1b trial for recurrent high-grade glioma, though the myositis, lupus, systemic sclerosis and myasthenia gravis programs all rely on the same rese-cel construct manufactured by contract development and manufacturing organizations. The company plans to launch with multiple manufacturing suppliers to build in redundancy and has partnered with Cellares Corporation since 2023 to incorporate automated manufacturing intended to scale rese-cel production for thousands of patients with minimal capital investment.
Show full overview
Cabaletta's near-term value is concentrated in a single construct: rese-cel is the company's lead product candidate across all five ongoing RESET trials, so a safety signal, a missed registrational endpoint, or a manufacturing setback in any one indication could affect the read-through for every other autoimmune indication the company is pursuing with the same CD19-CAR T therapy. The FDA's November 2023 investigation into T cell malignancies following CD19-directed autologous CAR T immunotherapies, and the resulting boxed-warning labeling requirement announced in January 2024, illustrate a class-wide regulatory risk that could weigh on rese-cel independent of Cabaletta's own trial data.
See also: Healthcare · Biotechnology
From Cabaletta Bio, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinerese-cel10-K Item 1: 'Resecabtagene autoleucel, or rese-cel...our lead product candidate within the CARTA strategy.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Volatile — 6.8% daily ATR makes tight stops impractical. Position-size conservatively.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $3.20: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: High short interest: 18%; Elevated put/call ratio: 1.60; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $2.97. Score 4.5/10, moderate confidence.
Take-profit target: $3.54 (+11.0% upside). Prior stop was $2.97. Stop-loss: $2.97.
Concentration risk — Pipeline: rese-cel; DATA_ISSUE: analyst_target_implausible (raw $13.38 vs price $3.19 — ratio 4.2×). Rejected, falling back to technical TP.; Quality below floor (2.4 < 4.0).
Cabaletta Bio, Inc. trades at a P/E of N/A (forward -2.2). TrendMatrix value score: 5.0/10. Verdict: Sell.
16 analysts cover CABA with a consensus score of 4.2/5. Average price target: $13.
What does Cabaletta Bio, Inc. do?Cabaletta Bio is a late clinical-stage biotechnology company developing engineered T cell therapies, built on its CABA...
Cabaletta Bio is a late clinical-stage biotechnology company developing engineered T cell therapies, built on its CABA platform, designed to reset the immune system for patients with autoimmune diseases through a one-time cell infusion. Its lead candidate, rese-cel, is in a registrational trial for dermatomyositis and anti-synthetase syndrome and Phase 1/2 trials across lupus, systemic sclerosis and myasthenia gravis, with a Biologics License Application for myositis anticipated in 2027. The company has not generated product revenue and relies on third-party CDMOs, including Cellares' automate